Abstract | BACKGROUND:
Topotecan is a topoisomerase I inhibitor that has good penetration across the blood-brain barrier and significant antitumor activity against human brain tumor xenografts. In a Phase I trial in children with refractory cancer, topotecan was well tolerated when administered as a 24-hour infusion. The maximum tolerated dose was 5.5 mg/m2 and the dose-limiting toxicity was myelosuppression. This Phase II study of topotecan was performed to assess the activity of topotecan against childhood brain tumors. METHODS: RESULTS: There were no complete or partial responses in the patients with high grade glioma (n=9), medulloblastoma (n=9), or brain stem glioma (n=14). One of 2 patients with a low grade glioma had a partial response lasting more than 17 months; 3 patients with a brain stem glioma had stable disease for 12 to 28 weeks; and 1 patient with a malignant neuroepithelial tumor and 1 patient with an optic glioma had stable disease for 41 weeks and 22 weeks, respectively. Dose escalation from 5.5 mg/m2 to 7.5 mg/m2 was well tolerated in the first 11 patients enrolled on this study who had not received prior craniospinal radiation therapy. The starting dose was subsequently increased to 7.5 mg/m2 for patients without prior craniospinal radiation. CONCLUSIONS:
|
Authors | S M Blaney, P C Phillips, R J Packer, R L Heideman, S L Berg, P C Adamson, J C Allen, S E Sallan, R I Jakacki, B J Lange, G H Reaman, M E Horowitz, D G Poplack, F M Balis |
Journal | Cancer
(Cancer)
Vol. 78
Issue 3
Pg. 527-31
(Aug 01 1996)
ISSN: 0008-543X [Print] United States |
PMID | 8697400
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Topotecan
- Camptothecin
|
Topics |
- Adolescent
- Adult
- Antineoplastic Agents
(administration & dosage, adverse effects, therapeutic use)
- Brain Neoplasms
(drug therapy)
- Brain Stem
- Camptothecin
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Child
- Child, Preschool
- Drug Administration Schedule
- Female
- Glioblastoma
(drug therapy)
- Glioma
(drug therapy)
- Humans
- Infant
- Infusions, Intravenous
- Male
- Topotecan
|